tiprankstipranks

Abbott price target lowered to $124 from $127 at Raymond James

Raymond James lowered the firm’s price target on Abbott to $124 from $127 and keeps an Outperform rating on the shares. The underlying momentum is strong off of challenging comparisons even though Covid-testing comps distorted the reported results, the analyst tells investors in a research note. The testing comps will start to ease, which will help the growth optics, and Raymond James expects Abbott to continue to deliver a differentiated growth profile that should stand out in large cap healthcare.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue